News

Patients still benefit from Eisai and Biogen Alzheimer's drug after four years, study finds
Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years ...
Eli Lilly and Biogen/Eisai’s extension trials make waves in Alzheimer’s market
Lilly’s Kisunla and Biogen/Eisai’s Leqembi can both continue to slow Alzheimer's cognitive decline after more than three ...
Eisai/Biogen, Eli Lilly highlight long-term data backing Alzheimer’s drugs
Eisai (OTCPK:ESALF) and Eli Lilly (NYSE:LLY) on Wednesday announced data from long-term extension studies for their ...
Fierce Pharma2d
Biogen raises sales outlook as Leqembi awaits FDA decision on new dosing option
After beating quarterly earnings expectations and raising its full-year sales outlook from a previously forecast decline, ...
BioSpace2d
Biogen’s Leqembi Push Getting Easier as CEO Eyes Early-Stage Pipeline Restock
Rumors of Biogen’s disagreements with Eisai have been greatly exaggerated, CEO Chris Viehbacher said during a second quarter ...
BioSpace3d
Biogen, Eisai’s Leqembi Slows Alzheimer’s Progression Through 4 Years of Treatment
Long-term data presented at the Alzheimer’s Association International Conference show Leqembi can help patients stay in the ...
Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI® (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, ...
Biogen signals Leqembi sales gaining momentum, lifts profit forecast
Biogen raised its annual profit forecast and beat estimates for quarterly results on Thursday, as strong demand for its rare ...
WKRG2mon
Eisai projects Leqembi® revenue to total JPY 76.5 billion for fiscal ...
STOCKHOLM, May 15, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that Leqembi sales are expected to total JPY 76.5 billion (approximately SEK ...
KTLA2mon
Eisai projects Leqembi® revenue to total JPY 76.5 billion for ... - KTLA
STOCKHOLM, May 15, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that Leqembi sales are expected to total JPY 76.5 billion (approximately SEK ...